Recent Updates
Recently added Catalysts

REGN24493

Phase 1

Graves' Disease | Small molecule | Endocrine |Regeneron Pharmaceuticals, Inc.|Trials Updated: Oct 6, 2026

REGN24493 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment45

FDA Designations

No designations recorded

REGN24493 clinical trials

REGN24493 · 1 trial · 1 indication

Phase 1 1
NCT07861152Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)Graves' Disease
NOT YET_RECRUITING45 Analytics
PHASE1NOT YET_RECRUITING
Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)
Graves' Disease
NCT0786115245
Unlock trial analytics

Study Endpoints

Primary Endpoints

Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Up to approximately 68 weeks

Secondary Endpoints

Concentrations of REGN24493 in serum
Day 1 through Week 68
Serum Thyroid-Stimulating Hormone (TSH) levels
Day 1 through Week 68
Serum free T4 (fT4) levels
Day 1 through Week 68
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Dose EscalationEXPERIMENTAL -
Placebo ComparatorPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
REGN24493DRUGAdministered per the protocol.
PlaceboDRUGAdministered per the protocol.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Key Inclusion Criteria: 1. Has a diagnosis of Graves' Disease for at least 4 months prior to the screening visit 2. Has thyroid-stimulating hormone receptor antibody (TRAb) level above the upper limit of normal at the screening visit 3. Euthyroid at the screening visit and at least 4 weeks prior to...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 6, 2026NCT07861152NEW_TRIAL: changed
LOWOct 6, 2026NCT07861152NEW_TRIAL: changed

Explore more on BiopharmaWatch

Regeneron Pharmaceuticals, Inc. (REGN)Pipeline, catalysts, financials, insiders and newsGraves' Disease disease mapEvery company developing for Graves' Disease, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with RCompanies A to ZEvery biotech and pharma company we track